Levels of Biomarkers of Inflammation and Oxidative Stress in Serum and Aqueous of Patients with Polypoidal Choroidal Vasculopathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190506004

Enrollment

Registered

2019-05-06

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal choroidal vasculopathy Polypoidal choroidal vasculopathy afilbercepy eylea biomarker oxidative stress interleukin&#45

Interventions

Senile cataract patinet whom underwent cataract surgery (Phacoemulsification) in the admission,PCV patient whom underwent Intravitreal afilbercept injection every 4 weeks 3 dose then every 8 weeks 5 d

No Intervention No treatment,Active Comparator Drug

Control,Intravitreal afilbercept injection (PCV patient)

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: PCV patient group 1.age greater than 18 years 2.Diagnosis of PCV in each or both eyes without previous treatment except pneumatic displacement 3.Diagnosis of PCV followed fundus photo, polyp lesion from ICGA, and the diagnostic criteria of the EVEREST study 4.No other retinal diseases 5.Visit Maharaj Nakorn Chiang Mai hospital between 1st February 2017-31st January 2019 6.No arthlerosclerotic diseases or uncontrolled metabolic diseases control group 1.Diagnosis of Senile cataract in each or both eyes without previous treatment and need to go on cataract surgery in Maharaj Nakorn Chiang Mai hospita 2.No other eye diseases 3.Demographic data is correlated with PCV patient group 4.Consent was approved from patient

Exclusion criteria

Exclusion criteria: 1.Have condition that obscure the fundus photo picture 2.Have systemic inflammatory condition or Using drug that interfere the process of inflammatory reaction 3.Have previous intraocular surgery or intravitreal injection

Design outcomes

Primary

Measure	Time frame
biomarker between PCV patients and control group baseline (day 0) Serum and aqueous analysis	—

Secondary

Measure	Time frame
biomarker between respone and non-response PCV patients baseline (day 0), 8 weeks, 24 weeks, 48 weeks serum and aqueous analysis,biomarker in non-response PCV patients after treatment with N-acetyl cysteine 48 weeks serum and aqueous analysis	—

Countries

Thailand

Contacts

Public ContactThanaphat Chaovisitsaree

Departmemt of Ophthalmology, Faculty of medicine, Chiang Mai university

thanaphat.chaovi@gmail.com085-1069432

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026